Compare Incyte Corporation (INCY) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs State Street PDR S&P Retail ETF — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while State Street PDR S&P Retail ETF trades at $89.65. Which is the better fit depends on your goals.
| INCY | XRT | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $92.35 |
52-Week Low | $81.61 | $77.28 |
Enterprise Value | $20.04B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
